EGFR and lung adenocarcinoma: Although the efficacy of EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) for EGFR mutation‐positive lung adenocarcinoma has been demonstrated, their effectiveness for EGFR‐mutated squamous cell carcinoma remains unclear.